Hanmi devotes to human health to serve corporate social responsibility
We will pioneer a new way and make every endeavor to be an innovativeleading player in global pharmaceutical industry
Hanmi makes strenuous and enthusiasticefforts to develop new treatments fordiabetes, obesity, cancer, autoimmune and rare disease by focusing on R&D
Introducing focused drug pipeline in Progress
Exploring interactive list of R&D pipeline
At-a-glance view of R&D pipeline
1st fixed-dose combination drug introduced in Korea
Controls Hypertension and Dyslipidemia at single treatment
Treatment to patient not adequately controlled on agent double combo FDCs
Increased efficacy due to improved lipid level control
A novel treatment option for ED patients accompanied by BPH
40% of allergic rhinitis patients accompanied by asthma , 80% of asthma patients accompanied by allergic rhinitis
CE certified by SGS as a class-3 medical device
Dual release concept of Esomeprazole which can prevent NAB(Nocturnal Acid Breakthrough) symptom